RxDoctor Payments Data

Yvonne Wang, MD

Cornea and External Diseases Specialist · New Haven, CTNPI 1679953863

Payments from drug & device makers

$2,353in general payments, 2019–2025

Across 27 payments — averaging $87.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$919
  • Glaukos Corporation$693
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$217
  • Dompe US, Inc.$140
  • Rxsight Inc$135
  • Celularity Inc.$97
  • plus $151 from 3 others

What the payments were for

  • Travel & lodging$79634%
  • Food & beverage$1,53965%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$70,252
Medicare patients
225
Services billed
466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine49$49,569
XiidraLifitegrast38$44,333
Restasis MultidoseCyclosporine41$27,451
TyrvayaVarenicline Tartrate24$18,454
Cyclosporine38$11,981
RocklatanNetarsudil Mesylat/Latanoprost13$10,057
MieboPerfluorohexyloctane/Pf11$8,341
CequaCyclosporine14$8,096
Prednisolone Acetate131$6,233
ValacyclovirValacyclovir Hcl35$3,530
Brimonidine Tartrate29$2,988
Dorzolamide-TimololDorzolamide/Timolol/Pf22$2,654
Loteprednol Etabonate13$2,139
MoxifloxacinMoxifloxacin Hcl40$1,352
Timolol Maleate18$828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$18$52,67449 claims
Oyster Point Pharma, Inc.Tyrvaya$77$18,45424 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$217$2,13913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in New Haven

Where these figures come from

Is this you, or does something look wrong? →